ANN M GROOVER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- CALHOUN, GA
- NPI
- 1871664995
- Received
- $1,401,719 in 2,466 records, 2019 to 2025 ($1,353,133 general, $48,586 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 649 | $433,081 |
| 2025 | Research payment | 43 | $19,170 |
| 2024 | General payment | 340 | $197,001 |
| 2024 | Research payment | 50 | $25,306 |
| 2023 | General payment | 361 | $230,056 |
| 2023 | Research payment | 5 | $4,110 |
| 2022 | General payment | 292 | $169,506 |
| 2021 | General payment | 302 | $123,586 |
| 2020 | General payment | 157 | $77,755 |
| 2019 | General payment | 267 | $122,146 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 441 | $1,094,625 |
| Travel and Lodging | 740 | $135,886 |
| Consulting Fee | 18 | $60,589 |
| Research payment | 98 | $48,586 |
| Food and Beverage | 1,161 | $35,401 |
| Honoraria | 4 | $26,326 |
| Education | 4 | $304 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | IDORSIA PHARMACEUTICALS US INC | $22 | Food and Beverage | In-kind items and services | Quviviq Drug, Insomnia | 2025 | |
| 2025-12-17 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $822 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $822 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $822 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $822 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $446 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $446 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $446 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $446 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $257 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $257 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $257 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-17 | Teva Pharmaceuticals USA, Inc. | $257 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-12-10 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | Vanda Pharmaceuticals Inc. | $1,165 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-10 | Vanda Pharmaceuticals Inc. | $124 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-10 | Vanda Pharmaceuticals Inc. | $20 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-09 | Vanda Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-08 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $457 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $107 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $106 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $45 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-03 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-03 | Teva Pharmaceuticals USA, Inc. | $1,198 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-12-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $8 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-24 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-21 | Day One Biopharmaceuticals | $66 | Food and Beverage | In-kind items and services | OJEMDA Drug, ONCOLOGY | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $1,376 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $252 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $180 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $102 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-19 | Vanda Pharmaceuticals Inc. | $2,730 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-19 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | Vanda Pharmaceuticals Inc. | $965 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-19 | Vanda Pharmaceuticals Inc. | $28 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-19 | Vanda Pharmaceuticals Inc. | $20 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Teva Pharmaceuticals USA, Inc. | $3,894 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $141 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $125 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Teva Pharmaceuticals USA, Inc. | $88 | Travel and Lodging | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-18 | Teva Pharmaceuticals USA, Inc. | $29 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-18 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Consulting Fee | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $113 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $74 | Food and Beverage | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-13 | ABBVIE INC. | $176 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $114 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $107 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $5 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-12 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | Vanda Pharmaceuticals Inc. | $213 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-12 | Vanda Pharmaceuticals Inc. | $71 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-12 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | Vanda Pharmaceuticals Inc. | $21 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-11 | Teva Pharmaceuticals USA, Inc. | $2,995 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-11 | Teva Pharmaceuticals USA, Inc. | $61 | Travel and Lodging | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-10 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-10 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $1,011 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $301 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $266 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $121 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-06 | Vanda Pharmaceuticals Inc. | $63 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-04 | Vanda Pharmaceuticals Inc. | $2,370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-04 | Vanda Pharmaceuticals Inc. | $721 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-04 | Vanda Pharmaceuticals Inc. | $216 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-04 | Vanda Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-03 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-03 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $1,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $229 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $229 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $133 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $133 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $124 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $56 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $20 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $18 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $14 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-29 | Vanda Pharmaceuticals Inc. | $5 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $2,730 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $348 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $229 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $229 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $133 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $133 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $107 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $39 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $25 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $5 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-27 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-22 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-22 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $861 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $296 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $235 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $120 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | Vanda Pharmaceuticals Inc. | $87 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-21 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-20 | ABBVIE INC. | $79 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-20 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $621 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $259 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $129 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $78 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-16 | Vanda Pharmaceuticals Inc. | $62 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-15 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-15 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-15 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $5,738 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $661 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $235 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $231 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $129 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $120 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $35 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $10 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $5 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $478 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $306 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $117 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-10 | Teva Pharmaceuticals USA, Inc. | $446 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-10-10 | Teva Pharmaceuticals USA, Inc. | $257 | Research payment | Cash or cash equivalent | AUSTEDO Drug, Central Nervous System | TV50717-CNS-40223 | 2025 |
| 2025-10-09 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $446 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $184 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $118 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $105 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $104 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $70 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $41 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $25 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $21 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ABBVIE INC. | $5 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-07 | Neurocrine BioSciences, Inc. | $28 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-02 | ABBVIE INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $527 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $214 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $173 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $49 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $613 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $173 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $105 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $36 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $15 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-29 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $404 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $10 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $3 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $404 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $18 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $10 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $10 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-24 | ABBVIE INC. | $3 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | ABBVIE INC. | $199 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | ABBVIE INC. | $42 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-22 | Alkermes, Inc. | $19 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 |
The latest 200 records of 2,466.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Calhoun, GA, county Gordon County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Calhoun, GA | County Gordon County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 18,183 | 59,100 | 10,940,407 |
| Population, 2020 census P1 | 16,949 | 57,544 | 10,711,908 |
| Median age B01002 | 36.0 | 38.9 | 37.6 |
| Under 18 B01001 | 24.8% | 23.1% | 23.2% |
| 65 and over B01001 | 16.0% | 15.8% | 15.0% |
| Households B11001 | 6,633 | 21,348 | 4,074,366 |
| Foreign born B05002 | 10.6% | 7.9% | 11.2% |
| Median household income B19013 | $58,750 | $63,650 | $77,353 |
| Median family income B19113 | $69,580 | $74,417 | $93,754 |
| Per capita income B19301 | $30,894 | $32,658 | $40,924 |
| Poverty rate B17001 | 14.1% | 12.0% | 13.4% |
| Unemployment rate B23025 | 2.3% | 3.7% | 5.1% |
| Civilian labor force B23025 | 8,437 | 28,590 | 5,496,061 |
| Mean commute (minutes) B08013 | 20.8 | 25.3 | 28.3 |
| Bachelor's degree or higher B15003 | 20.2% | 18.8% | 34.9% |
| Housing units B25001 | 7,199 | 23,562 | 4,541,835 |
| Owner-occupied B25003 | 55.8% | 73.9% | 65.7% |
| Renters B25003 | 44.2% | 26.1% | 34.3% |
| Median home value B25077 | $251,000 | $222,900 | $303,300 |
| Median gross rent B25064 | $873 | $937 | $1,393 |
| White, not Hispanic B03002 | 64.0% | 75.8% | 49.1% |
| Black B03002 | 6.6% | 3.4% | 30.7% |
| Hispanic or Latino B03002 | 24.8% | 16.3% | 11.0% |
| Asian B03002 | 0.7% | 0.9% | 4.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Calhoun, GA.
Comments